logo
Richard Garwin, designer of the first H-bomb who also paved the way for MRI, GPS and touch-screens

Richard Garwin, designer of the first H-bomb who also paved the way for MRI, GPS and touch-screens

Yahoo11-06-2025

Richard Garwin, who has died aged 97, was an American nuclear scientist who designed the world's first hydrogen bomb and went on to become a presidential adviser on arms control, while helping to lay the groundwork for such technology as magnetic resonance imaging, high-speed laser printers and touch-screen monitors. The Nobel prizewinner Enrico Fermi called him 'the only true genius I have ever met', but he never became a household name: a 2017 biography was subtitled 'The Most Influential Scientist You've Never Heard Of'.
Edward Teller is usually credited, in an unattributed phrase, as the 'father of the sweet technology of the H-bomb'. Due to the secrecy surrounding its development, it was only in recent years that historians have become aware of Garwin's role, following the publication in 2001 of a transcript of a recording made by Teller in which, while not eschewing the credit for devising the bomb, the scientist recalled that the 'first design was made by Dick Garwin'.
In 1951 Garwin, then a 23-year-old faculty member at the University of Chicago, was working during his summer holidays at the Los Alamos National Laboratory in New Mexico where, building on Teller's ideas, he designed the 'Mike', an 82-ton sausage-shaped test device, after working out how to direct the radiation from the atomic device to initiate a fusion reaction in the hydrogen – what he called 'the match for the nuclear bonfire'.
'The shot was fired almost precisely according to Garwin's design,' Teller recalled, on Enewetak Atoll on November 1 1952. The power of the blast – 450 times that of Nagasaki – stunned even those who had watched previous bomb tests, with a mushroom cloud five times the height of Everest and 100 miles wide.
Teller subsequently became famous for destroying the career of Robert Oppenheimer, who had run the Los Alamos lab in the Second World War, giving birth to the atomic bomb, but afterwards questioned the morality of devising an even more powerful weapon. When, amid the anti-communist paranoia of the McCarthy years, Oppenheimer had his security clearance removed by the government, Teller was the only member of the scientific community to testify against him.
In fact Garwin, a board member of the Union of Concerned Scientists, had a lot of sympathy with Oppenheimer, telling an interviewer that if he could wave a magic wand to make the H- bomb go away, 'I would do that.' But as the clock could not be wound back, he believed that the best hope for human survival lay in the deterrence doctrine of Mutual Assured Destruction (MAD) that suggests that a nuclear attack by one superpower would result in a retaliatory nuclear strike, leading to the complete destruction of both attacker and defender. 'The capability for MAD,' Garwin said 'is not a theory, but a fact of life'.
In the 1980s, when Teller convinced President Ronald Reagan to invest in a defensive shield that, he claimed, would make it probable that enough Americans would survive a nuclear conflict to ensure the US's continued existence, Garwin was vocal in his criticism of the so-called 'Star Wars' initiative as ineffective and wasteful. He saw a Soviet-American balance of weaponry and arms-control measures as the best way of avoiding nuclear Armageddon.
Richard Lawrence Garwin was born in Cleveland, Ohio, on April 19 1928, the older of two sons of Robert Garwin and Leona, née Schwartz. His father was a high school teacher; his mother a legal secretary.
From Cleveland Heights High School Garwin graduated in physics in 1947 from what is now Case Western Reserve University, followed by a master's degree and doctorate under Enrico Fermi at the University of Chicago. He joined the faculty, but at Fermi's suggestion spent his summers at the Los Alamos lab, where he returned every year until 1966.
For 40 years from the early 1950s Garwin was a researcher at IBM, maintaining a faculty position at Columbia University and advising presidents (excepting Reagan) from Eisenhower to Clinton on nuclear weapons and arms-control issues.
As a researcher he contributed to a huge range of scientific discoveries and innovations, and in 2016, when he was presented with the Presidential Medal of Freedom by Barack Obama, the president recalled: 'Ever since he was a Cleveland kid tinkering with his father's movie projectors, he's never met a problem he didn't want to solve. Reconnaissance satellites, the MRI, GPS technology, the touch-screen – all bear his fingerprints. He even patented a mussel washer for shellfish: that, I haven't used. The other stuff I have.'
In 1991 Garwin chaired a conference to discuss solutions to staunching the Kuwaiti oil leaks during the first Gulf War. He advised the Obama government on dealing with the Deepwater Horizon oil spill in the Gulf of Mexico and the Fukushima nuclear disaster in Japan. From 1993 to 2001 he chaired the State Department's Arms Control and Nonproliferation Advisory Board.
His belief in the vital importance of nuclear balance led him to oppose any policy that might upset that balance. In 2007, in evidence to the British Commons Defence Select Committee, he described Prime Minister Tony Blair's claim that work must start soon on replacing the ageing Vanguard-class subs of Britain's nuclear submarine fleet as 'highly premature''. The subs' working life could be extended to 45 years or more, he argued, putting off the need for a replacement into the late 2030s or beyond.
In 2021 he was one of 700 signatories to an open letter to President Biden, asking him to pledge that the US would never be the first to use nuclear weapons in a conflict and calling for curbs on his role as sole authority in ordering the use of nuclear weapons – as 'an important safeguard against a possible future president who is unstable or who orders a reckless attack'.
The plea fell on deaf ears.
In 1947 Richard Garwin married Lois Levy. She died in 2018, and he is survived by two sons and a daughter.
Richard Garwin, born April 19 1928, died May 13 2025
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Texas politicians lead effort to study a psychedelic drug. What is ibogaine?
Texas politicians lead effort to study a psychedelic drug. What is ibogaine?

USA Today

timean hour ago

  • USA Today

Texas politicians lead effort to study a psychedelic drug. What is ibogaine?

Ibogaine is illegal in the U.S., but growing evidence shows its promise treating the effects of traumatic brain injury and substance use disorder. A once obscure traditional psychedelic plant from Africa has made headlines recently as Texas pushes for more research and a prominent Republican wrote a vigorous endorsement of its possible use for the treatment of addiction and for veterans experiencing mental health issues. Ibogaine is illegal for use in the United States, but a growing body of evidence has shown its promise treating the effects of traumatic brain injury and substance use disorder. Earlier in June, Texas Gov. Greg Abbott signed legislation to allocate $50 million for clinical trials approved by the Food and Drug Administration to study ibogaine. Texas is set to lead research into the drug's benefits treating mental health issues and addiction as a potential medication. Former Energy Secretary Rick Perry, also a former Texas governor, wrote a June 27 Washington Post op-ed supporting ibogaine research and criticizing the legacy of the war on drugs, started by President Richard Nixon and touted by President Ronald Reagan. Perry said he has 'come to realize just how wrong that narrative was.' 'That fear-based messaging kept us from exploring treatments that could have saved countless lives,' Perry wrote. Perry and a growing number of conservatives have argued ibogaine could be one of those treatments. Here's what to know about the drug. What is ibogaine? Ibogaine derives from the root of the iboga plant native to western-central Africa. It's been used in ceremonial rituals for centuries. It has hallucinogenic properties. The United States outlawed ibogaine in 1967 along with other psychotropic drugs. The Controlled Substances Act of 1970 placed it as a schedule I hallucinogenic drug, along with marijuana. Ibogaine's classification prevented researchers from studying its effects. But unlike other schedule 1 drugs such as heroin, ibogaine has anti-addictive properties. There are risks since ibogaine can delay the body's normal electrical signals that control heart rhythm, which could lead to death. Other countries, such as Mexico, have allowed its use. American veterans and others have traveled to smaller, clandestine clinics for treatment to deal with depression, post-traumatic stress disorder and addiction. Many clinics are along the border and around cities such as Tijuana. Why is it in the news? At the state and federal level, there is growing interest in studying psychedelic drugs to treat veterans and others. Texas passed legislation earlier in June to study the drug with a public university alongside a company and hospital, Abbott's office said. Dr. Marty Makary, the FDA commissioner, has said expanding research on psychedelic drugs is a top priority for the Trump administration. In his op-ed, Perry cited the experiences of Morgan and Marcus Luttrell, twin combat veterans, who used ibogaine for recovery. Morgan Luttrell is now a Republican congressman from Texas who has advocated for ibogaine and other psychedelic drugs as treatment options. In January 2025, Perry and W. Bryan Hubbard, an advocate for ibogaine treatment, appeared on Joe Rogan's podcast to discuss ibogaine's benefits as a plant-based medicine. Hubbard led a Kentucky task force that sought to use opioid settlement funds to research ibogaine's effects to treat addiction, but the initiative failed to gain support in the state. Hubbard and Perry eventually launched the Texas Ibogaine Initiative, which helped spur the state funding. What has research shown? Research, such as a Stanford University study of 30 male combat veterans, has shown ibogaine's promise. Coupled with magnesium sulfate to address heart effects, ibogaine appeared to reduce symptoms of PTSD, anxiety and depression, and improve cognitive function from traumatic brain injury, according to the study, published in 2024 in the eminent journal Nature Medicine. Other studies have shown benefits treating addiction and depression. What do critics say? One issue with ibogaine is the ability to produce it, because it is derived from a rare plant and has mostly been used for ceremonial purposes. There is research to help innovate its safe production, but it could be difficult for the drug to be more widely available, as researchers at the University of California, Davis, Institute for Psychedelics and Neurotherapeutics have said. And while it's shown benefits with combat veterans, questions remain on its efficacy among randomized participants. With Texas' research, ibogaine could get closer to FDA approval for its use as a medication.

This New Test Could Diagnose Parkinson's With AI
This New Test Could Diagnose Parkinson's With AI

Newsweek

timean hour ago

  • Newsweek

This New Test Could Diagnose Parkinson's With AI

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A new artificial intelligence (AI) tool analyzing short smile videos achieved high accuracy in screening for Parkinson's disease (PD), according to research published by Tariq Adnan, and colleagues in the New England Journal of Medicine (NEJM) Thursday. The model was trained on the largest known video dataset of facial expressions to date, enrolling 1,452 participants, including 391 living with PD. An 87.9 percent overall accuracy in detecting PD using only smile video analysis, the NEJM AI study reported. Researchers reported that the AI model could accurately distinguish between individuals with and without PD based on the analysis of their smiles, even when applied in diverse population samples from North America and Bangladesh. Why It Matters The Parkinson's Foundation says an estimated 90,000 more people will be diagnosed this year, with the number of those suffering expected to be around 1.2 million by 2030. Diagnosing Parkinson's disease early remains a significant challenge because of limited access to clinical expertise and in-person evaluations. AI-driven remote screening tools promise scalable, cost-effective solutions to bridge these healthcare gaps. The findings align with the growing demand for digital healthcare solutions that remove geographical and economic barriers to early neurological disease diagnosis, which is especially relevant to rural and underserved American communities. What To Know The new screening method invited participants to record themselves mimicking facial expressions—including a smile—using an online platform. Research teams then extracted facial landmarks and measured action units to quantify hypomimia, a common motor symptom in PD where facial muscle movement is diminished. Machine learning models were developed using these features, distinguishing people with PD from those without. The approach relied on a broad recruitment strategy, involving participants from North America via social media, email, wellness centers, and research registries, alongside a high-risk cohort from Bangladesh. Trained solely on smile videos, the model achieved a 10-fold cross-validated accuracy of 87.9 percent, a sensitivity of 76.8 percent, and a specificity of 91.4 percent. Validation in external test sets revealed 80.3 percent accuracy in a U.S. clinic dataset and 85.3 percent accuracy in the Bangladesh cohort. While the negative predictive value remained above 92 percent in all settings, the positive predictive value dropped to 35.7 percent among the Bangladeshi participants, reflecting variations in population characteristics. The study found no significant differences in model performance across sex and ethnic subgroups, except for marginally higher accuracy in female participants in Bangladesh. The authors emphasized the generalizability and fairness of the approach, key considerations in the development of clinical AI tools. The video-processing and machine-learning code supporting the study is available to the public on GitHub. However, the study authors noted that raw video data sharing is restricted to comply with U.S. healthcare privacy law (HIPAA), limiting access to de-identified derivative features only. The research received funding from the National Institute of Neurological Disorders and Stroke at the National Institutes of Health, among other sources. The work was a collaborative effort involving academic and clinical partners such as the InMotion Parkinson's Disease wellness center and the University of Rochester Center for Health and Technology. The research process also benefited from contributions by staff at Google Research and the University of Rochester, particularly in statistical analysis. Stock image of brain MRI taken November 21, 2018. Stock image of brain MRI taken November 21, 2018. Getty What People Are Saying Tariq Adnan, lead author said in the study conclusion: "Smiling videos can effectively differentiate between individuals with and without PD, offering a potentially easy, accessible, and cost-efficient way to screen for PD, especially when access to clinical diagnosis is limited." What Happens Next? Future steps for the research team involve wider validation of the AI screening method in additional, real-world populations and further refinement of the algorithm to maximize early detection accuracy. Regulatory and clinical translation pathways will determine if and when this technology becomes available in the United States healthcare system.

Japan launches a climate change monitoring satellite on mainstay H2A rocket's last flight
Japan launches a climate change monitoring satellite on mainstay H2A rocket's last flight

The Hill

time2 hours ago

  • The Hill

Japan launches a climate change monitoring satellite on mainstay H2A rocket's last flight

TOKYO (AP) — Japan on Sunday launched a satellite to monitor greenhouse gas emissions using its mainstay H-2A rocket, which made its final flight before it is replaced by a new flagship designed to be more cost competitive in the global space market. The H-2A rocket successfully lifted off from the Tanegashima Space Center in southwestern Japan, carrying the GOSAT-GW satellite as part of Tokyo's effort to mitigate climate change. The satellite was released into orbit about 16 minutes later. Mitsubishi Heavy Industries, which operates the rocket launch, and Japan Aerospace Exploration Agency, will hold a news conference later Sunday to give further details of the flight. Sunday's launch marked the 50th and final flight for the H-2A, which has served as Japan's mainstay rocket to carry satellites and probes into space with a near-perfect record since its 2001 debut. After its retirement, it will be fully replaced by the H3, which is already in operation, as Japan's new main flagship. The launch follows several days of delays because of malfunctioning of the rocket's electrical systems. The GOSAT-GW, or Global Observing SATellite for Greenhouse gases and Water cycle, is a third series in the mission to monitor carbon, methane and other greenhouse gasses in the atmosphere. It will start distributing data in about one year, officials said. The liquid-fuel H-2A rocket with two solid-fuel sub-rockets developed by Japan Aerospace Exploration Agency has so far had 49 flights with a 98% success record, with only one failure in 2003. Mitsubishi Heavy Industries has provided its launch operation since 2007. H-2A successfully carried into space Japan's moon lander SLIM last year, and a popular Hayabusa2 spacecraft in 2014 to reach a distant asteroid, contributing to the country's space programs. Japan sees a stable, commercially competitive space transport capability as key to its space program and national security, and has been developing two new flagship rockets as successors of the H-2A series — the larger H3 with Mitsubishi, and a much smaller Epsilon system with the aerospace unit of the heavy machinery maker IHI. It hopes to cater to diverse customer needs and improve its position in the growing satellite launch market. The H3, is designed to carry larger payloads than the H-2A at about half its launch cost to be globally competitive, though officials say more cost reduction efforts are needed to achieve better price competitiveness in the global market. The H3 has made four consecutive successful flights after a failed debut attempt in 2023, when the rocket had to be destroyed with its payload.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store